ID Pharma Co Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ID Pharma Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014037
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ID Pharma Co Ltd (ID Pharma), formerly DNAVEC Corp is a manufacturer and commercializer of gene medicines. The company develops regenerative medicines, cell therapy, and other bio products. It offers vector platforms such as Sendai virus vector in its drug development process. ID Pharma’s vector technology is used to develop drugs in the bio-business classes such as gene therapy, gene vaccine, antibody, protein production and gene function analysis. The company develops gene therapies for cardiovascular, respiratory, autoimmune, ophthalmologic diseases, and cancer. Its gene vaccines are used for the treatment of tuberculosis, influenza, malaria, Alzheimer’s disease, tumor, and Parkinson’s disease. The company has operations in the US, Japan and China. ID Pharma is headquartered in Tsukuba, Japan.

ID Pharma Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ID Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
ID Pharma Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Life Technologies Extends R&D Agreement With Dnavec For CytoTune-iPS 2.0 Sendai Reprogramming Kit 11
DNAVEC Enters Into Research Agreement With I’rom Holdings 12
ID Pharma Enters into Co-Development Agreement with Shanghai Haigui Biosciences and Shanghai Public Health Clinical Center 13
Licensing Agreements 14
Axol Boscience Enters into Licensing Ageement with ID Pharma 14
Elixirgen Enters into Licensing Agreement with ID Pharma 15
Mayo Clinic Enters into Licensing Agreement with ID Pharma 16
Minerva Biotech Enters into Licensing Agreement with ID Pharma 17
Kohjin Bio to Enter into Licensing Agreement with ID Pharma 18
Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 19
DNAVEC Enters Into Licensing Agreement With RIKEN BioResource Center 20
DNAVEC Enters Into Licensing Agreement With International AIDS Vaccine Initiative For Prophylactic AIDS Vaccine 21
DNAVEC Enters Into Licensing Agreement With Chinese Company For Tumor Therapeutics 22
DNAVEC Enters Into Licensing Agreement With iPS Academia For iPS Cells 23
ID Pharma Co Ltd – Key Competitors 24
ID Pharma Co Ltd – Key Employees 25
ID Pharma Co Ltd – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Joint Venture 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ID Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ID Pharma Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
ID Pharma Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Life Technologies Extends R&D Agreement With Dnavec For CytoTune-iPS 2.0 Sendai Reprogramming Kit 11
DNAVEC Enters Into Research Agreement With I'rom Holdings 12
ID Pharma Enters into Co-Development Agreement with Shanghai Haigui Biosciences and Shanghai Public Health Clinical Center 13
Axol Boscience Enters into Licensing Ageement with ID Pharma 14
Elixirgen Enters into Licensing Agreement with ID Pharma 15
Mayo Clinic Enters into Licensing Agreement with ID Pharma 16
Minerva Biotech Enters into Licensing Agreement with ID Pharma 17
Kohjin Bio to Enter into Licensing Agreement with ID Pharma 18
Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 19
DNAVEC Enters Into Licensing Agreement With RIKEN BioResource Center 20
DNAVEC Enters Into Licensing Agreement With International AIDS Vaccine Initiative For Prophylactic AIDS Vaccine 21
DNAVEC Enters Into Licensing Agreement With Chinese Company For Tumor Therapeutics 22
DNAVEC Enters Into Licensing Agreement With iPS Academia For iPS Cells 23
ID Pharma Co Ltd, Key Competitors 24
ID Pharma Co Ltd, Key Employees 25
ID Pharma Co Ltd, Joint Venture 26

★海外企業調査レポート[ID Pharma Co Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Massachusetts Institute of Technology:企業のM&A・事業提携・投資動向
    Massachusetts Institute of Technology - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Massachusetts Institute of Technology Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • Public Power Corporation SA:発電所・企業SWOT分析
    Public Power Corporation SA - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key e …
  • Anchiano Therapeutics Ltd (BICL):製薬・医療:M&Aディール及び事業提携情報
    Summary Anchiano Therapeutics Ltd (Anchiano) formerly BioCancell Ltd, focuses on the identification, development and commercialization of therapies for diagnosis and treatment of cancer-related diseases such as superficial bladder carcinoma, pancreatic cancer and ovarian cancer. The company's produc …
  • Dexia Group:企業のM&A・事業提携・投資動向
    Dexia Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dexia Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • John Paul Mitchell Systems, Inc.:企業の戦略・SWOT・財務情報
    John Paul Mitchell Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary John Paul Mitchell Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Nostra Terra Oil and Gas Company Plc (NTOG):石油・ガス:M&Aディール及び事業提携情報
    Summary Nostra Terra Oil and Gas Company Plc (NTOG) is an oil and gas company. The company explores, produces, and develops oil and gas properties across the US. It holds interest in operating and non-operating working interests in its projects located in Texas, New Mexico, Wyoming, Kansas, Colorado …
  • ImmunoGen Inc (IMGN):企業の財務・戦略的SWOT分析
    ImmunoGen Inc (IMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • PricewaterhouseCoopers LLP:企業の戦略的SWOT分析
    PricewaterhouseCoopers LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • ARK Diagnostics Inc:企業の製品パイプライン分析
    Summary ARK Diagnostics Inc (ARK Diagnostics) is a developer, manufacturer and commercializer of in vitro diagnostic immunoassay products. The company's products include protease inhibitors, levetiracetam assay, topiramate assay, non-nucleoside reverse transcriptase inhibitors, gabapentin assay, lam …
  • United Microelectronics Corporation (2303):企業の財務・戦略的SWOT分析
    United Microelectronics Corporation (2303) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Petrol dd Ljubljana (PETG):企業の財務・戦略的SWOT分析
    Petrol dd Ljubljana (PETG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • BCD Travel Services B.V.:企業の戦略・SWOT・財務情報
    BCD Travel Services B.V. - Strategy, SWOT and Corporate Finance Report Summary BCD Travel Services B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Oiltanking GmbH:石油・ガス:M&Aディール及び事業提携情報
    Summary Oiltanking GmbH (Oiltanking), a subsidiary of Marquard & Bahls AG is an independent tank storage service provider. The company offers storage facilities and associated services for oils, petroleum products, chemicals, biofuels, gases and dry bulk. It owns and operates terminals in Europe, No …
  • Development Center for Biotechnology:製薬・医療:M&Aディール及び事業提携情報
    Summary Development Center for Biotechnology (DCB) is a non profit organization that offers support to biotechnology and pharmaceutical companies. The organization develops biotech industry through its cooperation and industrialization, key technologies, infrastructure building, research and develop …
  • Arno Therapeutics Inc (ARNI)-製薬・医療分野:企業M&A・提携分析
    Summary Arno Therapeutics Inc (Arno) is a clinical stage biopharmaceutical company that develops products for the treatment of cancer, infectious diseases and other life threatening diseases. The company has exclusive worldwide rights for the development and commercialization of Onapristone (for the …
  • PJSC Detsky Mir (DSKY):企業の財務・戦略的SWOT分析
    PJSC Detsky Mir (DSKY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • EMCORE Corporation (EMKR):企業の財務・戦略的SWOT分析
    EMCORE Corporation (EMKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Mr. Price Group Ltd.
    Mr. Price Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mr. Price Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Bilfinger SE:企業のM&A・事業提携・投資動向
    Bilfinger SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bilfinger SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Bumi Armada Bhd (ARMADA):石油・ガス:M&Aディール及び事業提携情報
    Summary Bumi Armada Bhd (Bumi Armada) is an integrated offshore solutions provider. The company owns and operates Floating Production Storage & Offloading (FPSO), Offshore Support Vessels (OSV), pipelaying barges, and subsea vessels. Its FPSO portfolio includes Armada TGT 1, Armada Sterling, Armada …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆